Liu, Chengfei
Armstrong, Cameron M.
Ning, Shu
Yang, Joy C.
Lou, Wei
Lombard, Alan P.
Zhao, Jinge
Wu, Chun-Yi http://orcid.org/0000-0003-2642-0380
Yu, Aiming http://orcid.org/0000-0003-1441-4012
Evans, Christopher P.
Tepper, Clifford G. http://orcid.org/0000-0001-7105-1102
Li, Pui-kai
Gao, Allen C. http://orcid.org/0000-0002-5966-9038
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA225836)
United States Department of Defense | United States Army | US Army Corps of Engineers | Engineer Research and Development Center (DOD PC150229)
U.S. Department of Veterans Affairs (I01BX0002653, IK6BX005222)
Article History
Received: 6 January 2021
Revised: 9 June 2021
Accepted: 17 June 2021
First Online: 16 July 2021
Competing interests
: PKL and ACG are co-inventors of a patent application of the small molecule inhibitors of androgen receptor variants (ARVib). All other authors declare no competing interests.